Cholesterol-lowering drugs may reduce cardiovascular death in type 2 diabetes, according to a recent study.

Findings by researchers at Wake Forest Baptist Medical Center suggest that the use of cholesterol-lowering statins could help prolong the lives of people with diabetic cardiovascular disease.

"Although our study was not a clinical trial, it did show that people with diabetes and heart disease can still live quite a few years by taking statins," Don Bowden, lead author of the study and professor of biochemistry at Wake Forest Baptist, said in a statement.

For the study, researchers studied data from 371 patients who had participated in the Diabetes Heart study. At the beginning of the study, the participants received a CT scan to determine their levels of coronary artery calcium (CAC); a CAC score greater than 1,000 indicates an increased risk for cardiovascular disease (CVD).

The research team compared the baseline characteristics of 153 patients who died during an average 8.2 years of follow-up and 218 who survived. The researchers assumed that risk for mortality would be consistently high among the study participants. However, 60 percent were still living after more than eight years.

Based on their findings, the participants taking statins at the beginning of the study had a 50 percent increase of being alive as compared to those who didn't.

Heart disease and stroke are the leading causes of death and disability among people with Type 2 diabetes. According to the American Heart Association, at least 65 percent of people with diabetes die from some form of heart disease or stroke.

Researchers said the findings highlights the importance of widespread prescription of cholesterol-lowering medications among individuals with Type 2 diabetes who have existing high CVD risk. In previous studies, the rates of satins prescribed for diabetic patients have been low.

"These data suggest that cholesterol-lowering medications may be used less than recommended and need to be more aggressively targeted as a critical modifiable risk factor," Bowden said.

The study was recently published in the current online edition of Diabetes Care.